Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qlife Holding ABOSTO:QLIFE +1.02%18 Receivables Turnover is 1.11 as of Mar. 2026. GuruFocus rates OSTO:QLIFE with a GF Score™ of 18/100 and a GF Value™ of kr0.75 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Qlife Holding AB ranks better than 82.27% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Qlife Holding AB's Revenue for the
three
months ended in Mar. 2026 was kr0.02 Mil. Qlife Holding AB's average Accounts Receivable for the
three
months ended in Mar. 2026 was kr0.02 Mil.
Hence, Qlife Holding AB's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.11.
Qlife Holding AB (OSTO:QLIFE) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Qlife Holding AB Receivables Turnover Related Terms
Qlife Holding AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Qlife Holding AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:QLIFE vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Qlife Holding AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qlife Holding AB Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Qlife Holding AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Qlife Holding AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qlife Holding AB (OSTO:QLIFE) has a Receivables Turnover of 1.11 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Qlife Holding AB and its competitors. According to the industry distribution chart, Qlife Holding AB ranks #144 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 17.7%.
Is Qlife Holding AB's Receivables Turnover too high?
Qlife Holding AB's current Receivables Turnover is 1.11. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Qlife Holding AB's value of 1.11 is 79.9% below this industry median. Based on the distribution chart, Qlife Holding AB ranks #144 out of 812 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Qlife Holding AB has a GF Score™ of 18/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qlife Holding AB's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Qlife Holding AB ranks #144 out of 812 companies for Receivables Turnover. This places Qlife Holding AB in the top 18% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.51. Qlife Holding AB's value of 1.11 is 79.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qlife Holding AB's current Receivables Turnover of 1.11 is 79.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Qlife Holding AB and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qlife Holding AB's current Receivables Turnover is 1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qlife Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Qlife Holding AB (OSTO:QLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.75, compared to a current price of kr1.99 — trading 164.8% above its estimated fair value. The current Receivables Turnover is 1.11 and 79.9% below the Medical Devices & Instruments industry median of 5.51. Qlife Holding AB's overall GF Score™ is 18/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Qlife Holding AB (OSTO:QLIFE), the current Receivables Turnover is 1.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qlife Holding AB (OSTO:QLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, Qlife Holding AB stock appears to be overvalued.
The current stock price of kr1.99 is trading 164.8% above its estimated GF Value™ of kr0.75.
GuruFocus considers Qlife Holding AB to be Significantly Overvalued.
Key valuation signals for OSTO:QLIFE:
Receivables Turnover: 1.11
GF Value™: kr0.75 vs. price of kr1.99 (164.8% above fair value)
Industry Position: 79.9% below the Medical Devices & Instruments median (#144 of 812)
No single metric tells the full story. See the OSTO:QLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qlife Holding AB is a medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it. The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient's doctor, clinic or hospital via smartphone and computer.
18GF Score
Get the complete analysis for OSTO:QLIFE
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:QLIFE has been successfully added to your 
